A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

  title={A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition},
  author={A. Clarke and F. Brewer and E. Johnson and N. Mallard and F. Hartig and S. Taylor and T. Corn},
  journal={Journal of Neural Transmission},
  • A. Clarke, F. Brewer, +4 authors T. Corn
  • Published 2003
  • Chemistry, Medicine
  • Journal of Neural Transmission
  • Summary. Seven randomised comparative studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption “Zydis Selegiline” (1.25–10 mg) with conventional selegiline hydrochloride tablets “conventional selegiline tablets” (10 mg). A total of 156 healthy volunteers participated in these studies. Plasma concentrations of selegiline and its primary metabolites, N… CONTINUE READING
    126 Citations
    A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    • 53
    Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
    • 34
    • Highly Influenced
    • PDF
    Selegiline: a molecule with innovative potential
    • 5
    • PDF
    The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
    • 12
    • Highly Influenced
    • PDF
    Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease
    • 60
    Selegiline Transdermal System: In the Treatment of Major Depressive Disorder


    Clinical Pharmacokinetics and Pharmacodynamics of Selegiline
    • 96
    The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    • 18
    • Highly Influential
    Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
    • 285
    Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    • 77
    • Highly Influential
    The molecular pharmacology of L-deprenyl.
    • 97
    R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    • J. Knoll
    • Chemistry, Medicine
    • Journal of neural transmission. Supplementum
    • 1987
    • 111
    Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
    • 144
    Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo
    • 117
    Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl
    • 244
    CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
    • 90
    • PDF